Truist Maintains Hold on Medtronic (MDT), Seeks Stronger EPS Growth

Medtronic plc (NYSE:MDT) is included among the Top 10 Income Stocks with the Highest Upside Potential.

Truist Maintains Hold on Medtronic (MDT), Seeks Stronger EPS Growth

On June 4, Truist reduced its price recommendation on Medtronic plc (NYSE:MDT) to $86 from $95. It reiterated a Hold rating on the shares. The firm pointed to a stronger-than-expected fourth quarter on the revenue side, with organic revenue growth coming in ahead of expectations. Margins, though, were softer than anticipated, while fiscal 2027 guidance largely matched forecasts. In its research note, Truist said it would need to see earnings per share growth move beyond the mid-single-digit to high-single-digit range before taking a more positive view on the stock.

Goldman Sachs analyst David Roman also trimmed his price target on Medtronic, lowering it to $83 from $84 while maintaining a Neutral rating. Roman said the company delivered fourth-quarter results that exceeded consensus expectations for organic revenue growth. Even with that stronger top-line performance, Goldman Sachs lowered its fiscal 2027 EPS estimate to $5.91 from $6.03. The adjustment was driven mainly by expectations for lower gross and operating margins, as well as the timing of Medtronic’s Diabetes spin-off.

Medtronic plc (NYSE:MDT) is an Ireland-based healthcare technology company that develops and provides medical technology solutions.

While we acknowledge the risk and potential of MDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MDT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best S&P 500 Dividend Stocks to Buy Right Now and Billionaire Larry Robbins’ 10 Dividend Stock Picks

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1